Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StrataMGT for Vulvar Lichen Sclerosus
NCT06662942Phase 1Recruiting
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in vulvar lichen sclerosus (LS) comparing StrataMGT with Placebo (2 arms). Primary endpoint: Vulvar Quality of Life Index 11 at 12 weeks. Started Oct 2024; status: recruiting.
02
Drugs
StrataXRT
03
Conditions
vulvar lichen sclerosus (LS)
Beyond the preview
Go deeper on NCT06662942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662942.